Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study.

Autor: Marsden JR; University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, U.K., Fox R; Cancer Research U.K. Clinical Trials Unit, School of Cancer Sciences, The University of Birmingham, Edgbaston, Birmingham, B15 2TT, U.K., Boota NM; Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, U.K., Cook M; Royal Surrey County Hospital, Guildford, U.K., Wheatley K; Cancer Research U.K. Clinical Trials Unit, School of Cancer Sciences, The University of Birmingham, Edgbaston, Birmingham, B15 2TT, U.K., Billingham LJ; Cancer Research U.K. Clinical Trials Unit, School of Cancer Sciences, The University of Birmingham, Edgbaston, Birmingham, B15 2TT, U.K., Steven NM; Cancer Research U.K. Clinical Trials Unit, School of Cancer Sciences, The University of Birmingham, Edgbaston, Birmingham, B15 2TT, U.K.

Publikováno v: The British journal of dermatology [Br J Dermatol] 2017 May; Vol. 176 (5), pp. 1148-1154. Date of Electronic Publication: 2017 Apr 10.